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Background: Patients with osteoporosis who receive tooth
extractions are typically on either oral bisphosphonate or
parathyroid hormone (PTH) therapy. Currently, the conse-
quence of these therapies on hard- and soft-tissue healing
in the oral cavity is not clearly defined. The aim of this
study is to determine the differences in the therapeutic ef-
fect on tooth-extraction wound healing between bisphosph-
onate and PTH therapies.
Methods: Maxillary second molars were extracted in
Sprague Dawley rats (n = 30), and either bisphosphonate
(zoledronate [Zol]), PTH, or saline (vehicle control [VC])
was administered for 10 days (n = 10 per group). Hard-
tissue healing was evaluated by microcomputed tomogra-
phy and histomorphometric analyses. Collagen, blood
vessels, inflammatory cell infiltration, and cathepsin K ex-
pression were assessed in soft tissue using immunohisto-
chemistry, quantitative polymerase chain reaction, and
immunoblotting.
Results: Both therapies significantly increased bone fill
and suppressed vertical bone loss. However, considerably
more devital bone was observed in the sockets of rats on
Zol versus VC. Although Zol increased the numbers of
blood vessels, the total blood vessel area in soft tissue
was significantly smaller than in VC. PTH therapy increased
osteoblastic bone formation and suppressed osteoclasts.
PTH therapy promoted soft-tissue maturation by suppress-
ing inflammation and stimulating collagen deposition.
Conclusion: Zoledronate therapy deters whereas PTH
therapy promotes hard- and soft-tissue healing in the
oral cavity, and both therapies prevent vertical bone loss.
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N
early one of four females and
one of eight males aged >50
years are diagnosed with oste-
oporosis in the United States.1,2 Pa-
tients with osteoporosis are typically
treated with either bisphosphonate
or teriparatide (recombinant human
parathyroid hormone [1-34]) therapy.
Bisphosphonates are antiresorptives
widely used for the management of
osteoporosis. More than 150 million
prescriptions were written for oral bi-
sphosphonates from 2005 to 2009.3
Conversely, teriparatide, a recombinant
human parathyroid hormone (PTH), is
a bone anabolic agent used for the
treatment of osteoporosis. More than 1
million patients around the world have
received teriparatide therapy since
2002.4 Hence, a large elderly pop-
ulation is currently on either bi-
sphosphonate or teriparatide therapy
for osteoporosis. Because tooth ex-
tractions are common dental pro-
cedures in the elderly,5,6 more patients
on bisphosphonate or teriparatide
therapy are likely to receive tooth ex-
tractions and subsequent implant
therapy. Therefore, it is crucial for
dentists to understand the effect of
these therapies on tooth-extraction
wound healing to establish better in-
formed consent and postextraction
care. Currently, how these drugs in-
fluence tooth-extraction wound healing
is not clearly defined.
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Tooth extractions cause tissue injuries, such as
mechanical damage in bony socket walls and soft-
tissue lacerations.7 Extraction wounds are typically
left exposed to the oral cavity in which many mi-
croorganisms reside. Accordingly, intense in-
flammatory responses occur after tooth extractions.8
Mechanical damage-induced osteocyte death in
bony socket walls manifests as necrotic bone
that prompts osteoclastic bone resorption for repair.
If this process does not occur, necrotic bone is re-
tained and the healing is incomplete. In rats, os-
teoclasts emerge in the crestal portion of socket
walls to resorb damaged bone at 2 days after ex-
tractions, resulting in a reduction of inflammatory
responses.9 The resolution of inflammation is in-
deed necessary to advance wound healing and
subsequent bone formation. In a previous study in
which osteopetrotic rats received tooth extractions,
more than one third of the rats developed in-
fections in tooth-extraction wounds and, even in
non-infected extraction wounds, bone fill was
considerably compromised compared with control
rats.10 Although mutant rats were used in the
study, the findings suggest that osteoclastic bone
resorption plays a pivotal role during healing of
tooth-extraction sockets.
Bisphosphonates suppress bone remodeling and
resorption by targeting osteoclasts.11 Because
osteoclastic resorption of damaged bone is an
essential step in tooth-extraction socket healing, it
is theorized that bisphosphonate therapy would
alter the normal osseous healing process in tooth-
extraction sockets. However, the incidence of
healing complications, such as infection and os-
teonecrosis of the jaw (ONJ) after tooth extrac-
tions among patients on oral bisphosphonates is
low.12 In the case of ONJ, the incidence is esti-
mated at 0.02%.13 Therefore, the majority of
tooth-extraction wounds heal successfully and
uneventfully in patients on oral bisphosphonates,
although osteoclasts are suppressed in these pa-
tients. Teriparatide (PTH) therapy increases bone
mass by promoting bone remodeling in favor of
bone formation versus resorption.14 The bone
anabolic effect of PTH therapy appears to be
enhanced when applied to osseous tissues in
which bone metabolism is active, such as fracture
sites15 and rapidly growing bones.16 In the cra-
niofacial region, PTH therapy improves the out-
come of periodontal surgeries17 and grafting
procedures in rat tooth-extraction sockets.18 Be-
cause bisphosphonate therapy suppresses and
PTH therapy enhances bone remodeling, the
healing pattern of tooth-extraction sockets would
be distinct between hosts on bisphosphonate or
PTH therapy.
In the present study, the effect of bisphosphonate
and PTH therapies on tooth-extraction wound
healing is investigated. The objectives are as fol-
lows: 1) to characterize, contrast, and compare how
bisphosphonate and PTH therapies affect the soft-
tissue healing process; and 2) to determine the
advantages and disadvantages of each therapy on
tooth-extraction wound healing.
MATERIALS AND METHODS
Animals, Tooth Extractions, and Antiresorptives
Thirty Sprague Dawley rats† (40 days old) were
obtained and randomly divided into three groups
(n = 10 per group). Sample size was determined by
power calculations to obtain 85% statistical power
by referring to a published study in which similar
experiments were performed.19 Rats were main-
tained at 22C and in 12-hour light/dark cycles.
Rats were allowed access to water and standard
rodent diet ad libitum. The maxillary left and right
second molars were extracted under general an-
esthesia (ketamine and xylazine mixture) using
dental instruments. PTH‡ was subcutaneously ad-
ministered daily at 80 mg/kg for 10 days, and zo-
ledronate (Zol)§ was subcutaneously administered
every 2 days at 0.1 mg/kg/week for 10 days (total
cumulative dose of 0.15 mg/kg) after tooth ex-
traction. These doses have been used previously
and reported.20,21 The vehicle control (VC) group
was administered an equivalent volume of saline.
The experimental design and protocol were re-
viewed and approved by the University of Michigan
Committee on Use and Care of Animals.
Microcomputed Tomography (micro-CT)
The maxillae (right half) were dissected, fixed in
10% formalin, and scanned using micro-CTi at 10-
mm voxel resolution with an energy level of 70 kV.
The trabecular compartment in the extraction
sockets and interradicular bone between the mesial
and distal roots of the maxillary first molars were
segmented by the semi-manual contouring method
and assessed using the built-in software program.¶
The vertical alveolar bone loss (ABL) was also
assessed by measuring the distance between
the cemento-enamel junction (CEJ) level of the
neighboring tooth and the crest of the bone in the
extraction wounds.
Immunohistochemistry
To understand the systemic effect of treatment,
proximal tibiae were histomorphometrically assessed
† Charles River Laboratories, Wilmington, MA.
‡ H4835, Bachem, Torrance, CA.
§ Zometa, Novartis, Basel, Switzerland.
i mCT 100, Scanco Medical, Bruttisellen, Switzerland.
¶ Scanco software, Scanco Medical.
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in addition to the maxillae. Tibiae were isolated,
fixed in 10% formalin, and then, along with the
maxillae, demineralized in 10% EDTA, paraffin
embedded, and sectioned at 5 µm. For tibial sec-
tions, hematoxylin and eosin (H&E) staining was
performed using a standard staining protocol.
Tartrate-resistant acid phosphatase (TRAP) staining
was also performed following the instructions of
the manufacturer.# For the maxillae, 15 serial
sections were prepared from each extraction
wound, and three serial sections were used for each
staining. Masson’s trichrome staining was con-
ducted to visualize collagen fibers following the
instructions of the manufacturer** in addition to
H&E and TRAP staining. Blood vessels and mac-
rophages were immunohistochemically visualized
in the wounds using von Willebrand factor (vWF)
and CD68 antibodies, respectively. Briefly, sections
were deparaffinized, and enzymatic epitope retrieval
was performed in 0.05% trypsin. Non-specific
protein was blocked with 10% goat serum. Sections
were incubated at 4C overnight with a rabbit
polyclonal vWF antibody†† at 1:800 and a mouse
monoclonal CD68 antibody‡‡ at 1:200. Endoge-
nous peroxidase activity was then blocked
with 0.3% hydrogen peroxide. Goat antirabbit im-
munoglobulin G (IgG)§§ and goat antimouse IgGii
conjugated to horseradish peroxidase (HRP) were
used for secondary antibody. Proteins were de-
veloped with 3,3-diaminobenzidine,¶¶ and sec-
tions were counterstained with hematoxylin and
mounted.
Hard- and soft-tissue healing in the extraction
wounds were histomorphometrically assessed in
three serial-stained sections.## Bone area fraction
(BAF) and osteoclast numbers per bone perimeter
(OC.N/BS) were analyzed in the proximal tibiae. OC.
N/BS, osteoblast surface per bone perimeter, and
empty osteocyte lacunae were analyzed in the
extraction socket walls as described previously.22
Empty osteocyte lacunae were quantified within
100-µm depth of bone surface in the sockets. Soft-
tissue healing was assessed by quantifying collagen
fibers, inflammatory cell (polymorphonuclear leu-
kocyte [PMN]) infiltration, blood vessels, and CD68+
mononuclear cells in the soft tissue overlying the
tooth-extraction socket (0.4 mm height · 2.5 mm
width). The results of the histomorphometric
measurement were averaged for the three serial
sections for each staining and used for analyses.
Quantitative Real-Time Polymerase Chain
Reaction (qPCR)
Approximately 8 mm3 (2 · 2 · 2 mm) of fresh soft
tissue overlying the tooth-extraction socket was
isolated and immediately frozen in liquid nitrogen.
Fresh bone marrow was isolated from femurs using
centrifugation23 and immediately frozen in liquid
nitrogen. A subset of soft-tissue specimens and
bone marrow were processed,*** and total RNA
was extracted by the phenol/chloroform method.
First-strand cDNA was synthesized.††† qPCR was
performed.‡‡‡§§§ Samples were run in triplicate,
and relative quantification of data generated using
this system was performed using the standard
curve method. The sets of primers used for qPCR
were as follows: 1) Cathepsin K (CTSK), 59-TGTCT
GAGAACTATGGCTGTGG-39 and 59-ATACGGG-
TAAGCGTCTTCAGAG-39; 2) Vitronectin, 59-TTA-
GAACACGGCGAGTGGAC-39 and 59-CTGTGTG




The remaining soft-tissue specimens and bone
marrow were used for protein analysis. The speci-
mens were homogenizediii to extract protein lysate.
Proteins (50 mg) were separated by a 4% to 10%
gradient polyacrylamide gel¶¶¶ and transferred to
nitrocellulose membranes.### The blots were
blocked with 5% non-fat milk for 1 hour at room
temperature and incubated with 1:750 rabbit anti-
CTSK antibody**** and 1:10,000 anti-tubulin an-
tibody†††† overnight at 4C in blocking buffer,
washed three times, followed by 1:10,000 HRP-
conjugated donkey antimouse‡‡‡‡ or antirabbit
secondary antibody.§§§§ The protein bands were
visualized on x-ray filmiiii after using an enhanced
chemiluminescence reagent.¶¶¶¶ Bands were then
densitometrically assessed using a software pro-
gram.####
Serum Calcium
Blood was collected from the tail vein before tooth
extractions and at euthanasia in anesthetized rats.
Serum samples were prepared and kept at -80C
# 386A, Sigma-Aldrich, St. Louis, MO.
** HT15, Sigma-Aldrich.
†† ab6999, Abcam, Cambridge, MA.
‡‡ MAB1435, Millipore, Billerica, MA.
§§ AP307, Millipore.
ii AP340P, Millipore.
¶¶ Vector Laboratories, Burlingame, CA.
## Image-Pro Plus, Media Cybernetics, Bethesda, MD.
*** TRIzol, Invitrogen, Grand Island, NY.
††† SuperScript First-Strand System, Invitrogen.
‡‡‡ iCycler iQ, Bio-Rad, Hercules, CA.




**** 30056, Santa Cruz Biotechnology, Santa Cruz, CA.
†††† T5168, Sigma-Aldrich.
‡‡‡‡ 2314, Santa Cruz Biotechnology.
§§§§ 2313, Santa Cruz Biotechnology.
iiii CL-Xposure Film, Pierce, Rockford, IL.
¶¶¶¶ Pierce.
#### NIH Image J Version 1.45, Bethesda, MD.
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until use. Serum calcium levels were measured*****
and compared before and after therapy.
Statistics
Data were analyzed with the Shapiro-Wilk test for
normality. Analysis of variance was performed for
multiple groups. Tukey’s test was used as a post
hoc test. For comparisons within the group,
a paired t test was conducted. No non-parametric
tests were used because the Shapiro-Wilk test
revealed that all datasets were parametric. Sta-
tistical analysis was conducted with a statistics
software program.††††† An a level of 0.05 was
used for statistical significance, and results are
presented as mean – SEM unless otherwise
specified.
RESULTS
Zoledronate Suppressed Osteoclasts and
Increased Bone Mass
PTH and Zol were administered to rats for 10
days, and the proximal tibiae were assessed to
determine their systemic effects in bone. Signifi-
cantly higher bone mass was noted in the PTH
and Zol groups versus VC (Figs. 1A and 1B). No
differences were noted in bone mass (BAF) be-
tween the PTH and Zol groups. OC.N/BS was no
different with PTH administration but was signifi-
cantly lower in the Zol group (Fig. 1C), suggesting
that the high bone mass in the Zol group is, at
least in part, at the expense of osteoclastic bone
resorption. In accordance with the suppressed
osteoclast surface, serum calcium levels were
significantly decreased by Zol (Fig. 1D). Thus, Zol
treatment for 10 days exerted significant anti-
resorptive effects in bone.
Zoledronate Increased Osteoclasts in Tooth-
Extraction Sockets
There were no differences noted in clinical gross
healing among groups (data not shown). Represen-
tative images of the trichrome-stained sections of
the healing wounds are shown (Fig. 2A). PTH sig-
nificantly increased osteoblast number and markedly
decreased OC.N/BS. Zoledronate had no effect on
osteoblasts (Figs. 2B and 2C) but substantially in-
creased OC.N/BS in the healing wounds compared
with VC. The numbers of empty osteocyte lacunae
were significantly higher in the Zol group compared
with other groups (Fig. 2D).
PTH and Zoledronate Enhanced Bone Fill in
Tooth-Extraction Sockets
To elucidate the effects of PTH and Zol on hard tissue
during tooth-extraction socket healing, wound areas
were assessed using micro-CT. Both PTH and Zol
significantly enhanced bone fill in the sockets com-
pared with VC (Fig. 2E) and also increased trabecular
bone thickness (Tb.Th). In addition, the vertical ABL
was significantly suppressed by both PTH and Zol
(Fig. 2F). Although both therapies affected hard-
tissue healing at the wound site, no effects were noted
in the interradicular intact bone (Fig. 3). Hence, both
therapies exerted their effects in osseous wounds
but not in intact bone of the maxillae.
PTH Promoted Soft-Tissue Healing
In the soft tissue overlying the tooth-extraction
socket, newly formed blood vessels were visualized
by vWF staining and quantified (Figs. 4A through
4C). Although Zol significantly increased the num-
bers of blood vessels, the total area of blood vessels
Figure 1.
Histomorphometric analysis of the proximal tibiae and serum calcium. A) Representative images of H&E-stained sections of the proximal tibiae. B)
Histomorphometric analysis showed significantly higher BAF in the proximal tibiae of the PTH and Zol groups compared with VC. C) TRAP staining
was performed, and TRAP-expressingmultinucleated cells (nucleus more than two) on the bone surfaces were counted. Zol therapy significantly suppressed
OC.N/BS versus VC. PTH did not alter OC.N/BS versus VC. D) Serum calcium levels were measured before and after the 10-day treatment regimen,
and results were compared using paired t test. Zol therapy significantly lowered serum calcium level after 10 days, but no change was noted in the VC and
PTH groups. n ‡8 per group. *P <0.01, †P <0.001.
***** Calcium Reagent Set (C7503), Pointe Scientific, Canton, MI.
††††† SYSTAT v.12, Systat Software, Chicago, IL.
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was lower when compared with the other groups,
suggesting that blood vessels in the Zol group were
smaller. No statistically meaningful differences were
noted in CD68+ macrophage numbers among
groups, although there was a trend noted in which
CD68+ macrophages were decreased in the PTH and
Zol groups compared to VC (Figs. 4D and 4E). PTH
significantly suppressed PMN infiltration and pro-
moted collagen formation, indicating enhanced soft-
tissue healing (Figs. 4F through 4H).
Differential CTSK Expression in Wounds
Depending on Treatment
CTSK in the soft tissue of the healing wounds and the
femoral bone marrow were assessed at the RNA and
protein levels. In the healing wounds, PTH signifi-
cantly suppressed CTSK at the RNA level, whereas
Zol increased the average CTSK level, although
statistical significance was not reached (Fig. 5A).
Because CTSK is abundant in osteoclasts,24 the
decreased CTSK expression in the healing wounds
were harmonious with decreased OC.N/BS in the
PTH group (Fig. 2C). However, at the protein level, no
significant differences were noted between the Zol
and VC groups, although a trend was observed that
Zol therapy increased CTSK (Fig. 5B). In the bone
marrow, no differences were noted in the CTSK
mRNA expression or protein levels among groups
(Figs. 5C and 5D).
DISCUSSION
Bisphosphonates and PTH are both used to treat
osteoporosis, but they are distinct in their actions in
bone. Bisphosphonates suppress osteoclastic bone
resorption, whereas PTH stimulates osteoblastic
bone formation.14 Because osteoclastic bone re-
sorption is a crucial component of tooth-extraction
socket healing, the fact that, clinically, tooth-
extraction wounds heal uneventfully in the majority
of patients on oral bisphosphonates raises the
question whether healing of tooth-extraction wounds
in this patient population are indeed physiologically
normal. This study finds that PTH suppressed in-
flammation, stimulated collagen synthesis, increased
osteoblastic bone formation, and suppressed oste-
oclasts, thereby collectively promoting soft- and
hard-tissue healing in the tooth-extraction wounds.
Conversely, Zol hindered osseous healing as evi-
denced by more empty osteocyte lacunae and had
an unfavorable impact on blood vessel formation in
soft tissue. Clinical significance of the increased
Figure 2.
Hard-tissue assessment in healing wounds.A) Representative images of trichrome-stained sections of tooth-extraction wounds.B) PTH therapy significantly
stimulated osteoblasts comparedwith VC.Nodifferenceswere noted in osteoblast number (OB.N/BS) betweenZol and VC. n‡ 8per group.C)PTH resulted
in considerably lower OC.N/BS versus VC, whereas Zol significantly increased OC.N/BS compared with VC. n ‡ 8 per group. D) The numbers of empty
osteocyte lacunae were counted in the socket walls of tooth-extraction sockets. Significantly higher numbers of empty lacunae were noted in the Zol group
compared to other groups. n ‡8 per group. E) Tooth-extraction sockets were semi-manually contoured and assessed. PTH and Zol therapies resulted in
significantly higher bone fill in the extraction sockets compared with VC. Significantly more bone fill was observed in the PTH group versus Zol. A similar trend
was noted in bone mineral density (BMD) and Tb.Th. No statistically significant differences were noted in the trabecular bone number (Tb.N) and
trabecular separation (Tb.Sp) between groups. n >7 per group. F) An imaginary straight line between the buccal CEJs of the neighboring molars was drawn
using the micro-CT software, and the distance between the line and the crestal bone in the extraction wounds was measured. Significantly smaller alveolar
ridge loss was found in the both PTH and Zol groups compared with VC. n >7 per group. *P <0.05, †P <0.01, ‡P <0.001.
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numbers of empty osteocyte lacunae in the sockets
by Zol is unknown. However, because this is
a common finding of studies about bisphosphonate
effects on oral osseous wound healing,7,25,26 bi-
sphosphonate therapy may weaken osteocyte re-
sistance to trauma-induced death. Under normal
healthy conditions, bone with empty osteocyte la-
cunae is indicative of dead bone, and osteoclastic
resorption initiates the repair process of such dead
bone. However, it is likely that dead bone is retained
because the repair process is not initiated as a result
of osteoclast suppression by bisphosphonates. This
would negatively affect overall tissue integrity.
The antiangiogenic property of bisphosphonates
has been implicated as a causal factor of ONJ.27
However, recent clinical trials have demonstrated
no association between antiangiogenic therapy and
the incidence of ONJ.28 The current study finds
that, in soft tissue overlying the tooth-extraction
socket wound, Zol therapy promoted blood vessel
formation yet the total area of blood vessels was
significantly smaller versus VC. Therefore, short-
term Zol therapy seems to have a negative effect
on soft-tissue wound healing. Conversely, PTH
therapy showed no effect on blood vessels in this
model but did strongly suppress PMN infiltration
and promoted soft-tissue repair by increasing col-
lagen deposition. Hence, short-term PTH therapy
promoted, but Zol therapy impeded, soft-tissue
healing around the extraction wounds.
In rats, epithelial coverage of extraction wounds
generally occurs by day 7, and the bottom half of
the extraction sockets are filled with woven bone by
day 10 and completely occupied by day 14.9,29
Because the initial stability of wounds is crucial for
subsequent healing events, the authors of the
present study chose to assess wound healing at 10
days after extraction. It was originally thought that
10 days of treatment would be enough to alter
tooth-extraction wound healing but not sufficient to
induce significant systemic effects in long bones.
However, both Zol and PTH resulted in significantly
higher bone mass in long bones compared to VC.
This is likely because young adult rats (40 days
old) were used. Rats at this age are still growing
skeletally, with bone formation exceeding re-
sorption.30 When Zol or PTH is administered in
growing mice, their effects in bone becomes evi-
dent in a relatively short period of time.16,31 This
explains why the effects of Zol and PTH are so
dramatic in this study. It should be mentioned that
the daily PTH dose of 80 mg/kg is used in this
study. The daily PTH dose for rats typically ranges
from 20 to 80 mg/kg in the literature.32-35 There-
fore, the dose used in the current study is con-
sidered relatively high, and this may also help to
explain the increased bone mass found in long
bones. In the proximal tibiae, the numbers of os-
teoclasts were significantly decreased by Zol but
no reduction was noted in the PTH group, sug-
gesting that increased bone mass in the Zol group
was essentially attributable to the suppression of
osteoclastic bone resorption, whereas in the PTH
group, the stimulation of bone formation accounted
for increased bone mass. Similar effects were
observed in the tooth-extraction wounds; both Zol
and PTH resulted in considerably high bone fill.
However, no such effects were noted in the in-
terradicular intact bone of the maxillae. This result
Figure 3.
Micro-CTanalysis of the interradicular bone. The interradicular bone of the
neighboring maxillary right first molars was assessed. No therapeutic
effect was noted among groups. n >7 per group.
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was anticipated because the sensitivity of the
craniofacial bone to PTH is lower than that of long
bones.36 Contrary to the tibiae, PTH and Zol ad-
ministration for 10 days was not long enough to
alter the microarchitecture of the intact maxillary
bone; in tooth-extraction wounds, bone metabolism
was so vigorous that clear therapeutic effects were
detected even in the maxillae.
It was interesting to note that Zol increased OC.N/
BS in tooth-extraction wounds despite the fact
that they were strongly suppressed in the tibiae.
Although OC.N/BS were elevated, Zol significantly
promoted bone fill in the extraction sockets, with no
impact on osteoblast numbers. This suggests im-
paired osteoclastic resorption of bone. In fact, the
vertical loss of the alveolar ridge was significantly
less in the Zol group versus VC. Because osteoclasts
are responsible for the vertical bone loss of the
alveolar crest,9,29,37 osteoclastic bone resorption is
suppressed at this site in the present study. There-
fore, Zol administration for 10 days did suppress
osteoclastic bone resorption in tooth-extraction
sockets. The discrepancy between the increased
OC.N/BS and the promoted bone fill in tooth-
extraction sockets in the Zol group can be explained
by increased numbers of non-functioning osteo-
clasts. Weinstein et al.38 reported that OC.N/BS
increased despite significantly suppressed bone
resorption in the biopsies of patients on bi-
sphosphonate therapy. When osteoclasts internalize
bisphosphonates, GTPase signaling is disrupted
and osteoclasts detach from bone surfaces because
of loss of the sealing zone.39-41 Therefore, in this
study, it is speculated that osteoclasts were gen-
erated but detached from the bone surfaces at-
tributable to the internalization of Zol, resulting in
Figure 4.
Soft-tissue assessment in healing wounds. A) Representative images of the vWF-stained sections of soft tissue in the healing wounds. Arrows
indicate vWF-expressing blood vessels. Scale bar = 0.1 mm. Sections were counterstained with hematoxylin. B and C) Zol therapy induced
significantly more blood vessels compared with VC. However, total blood vessel area was significantly smaller than the PTH and VC groups.
D) Representative images of the CD68-stained sections of the healing wounds are shown. Scale bar = 0.1 mm. E) Histomorphometric analysis
revealed a non-significant decrease in CD68+ macrophages in the PTH and Zol group compared to VC. F) PMN infiltration in the healing
wounds was assessed in H&E-stained sections. Both PTH and Zol therapies significantly reduced PMN infiltration with a substantial reduction by
PTH therapy. G) Representative images of the trichrome-stained sections of soft tissue in the healing wounds. Scale bar = 0.1 mm. Collagen
fibers were stained with blue color. H) Collagen fibers were histomorphometrically assessed. PTH considerably increased total collagen amount in
the overlying soft tissue. n >7 per group. *P <0.05, †P <0.01.
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increased non-resorbing osteoclasts in the wounds.
Hence, osteoclastic bone resorption was inefficient,
although many osteoclasts were noted in the ex-
traction sockets. In this study, the impacted soft
tissue overlying the tooth-extraction socket is as-
sessed for CTSK at the RNA and protein levels to
get an insight into osteoclasts in the extraction
wounds. PTH suppressed and bisphosphonate in-
creased CTSK expression at the RNA level, but no
significant differences were noted at the protein
level. Histomorphometric assessment revealed that
OC.N/BS were suppressed by PTH and increased
by Zol treatment. The discrepancy in the result
between protein and histomorphometric assess-
ments is likely attributed to difficulties in the tissue
collection. It was a great challenge to locate and
isolate the impacted soft tissue without also in-
cluding intact soft tissue in the small tooth-ex-
traction wounds. Therefore, protein lysates could be
contaminated from the intact tissue, which may
affect the expression of CTSK in the results. Also,
the connective tissue deep in the extraction wounds
near the bone could be missed during tissue col-
lection, and this too could cause a decrease in
differences among the groups because osteoclasts
exist on and near the bone surfaces.
Osteoporosis patients are generally being treated
with either bisphosphonate or teriparatide before
tooth extractions. In this study, Zol and PTH ad-
ministration are initiated when tooth extractions were
performed. To make the study more clinically rele-
vant, Zol and PTH could be given before the tooth
extractions. Nonetheless, with the present approach,
the effects of bisphosphonate and PTH on tooth-
extraction wound healing are explained in detail.
Moreover, this study discovered that PTH adminis-
tration starting immediately after tooth extractions
not only promoted osseous healing but also en-
hanced soft-tissue integrity in the extraction wounds.
Hence, although the present approach could be
improved, it was sufficient to achieve the study goals.
CONCLUSIONS
This study affirms that the healing pattern of tooth-
extraction sockets is distinct between Zol and PTH
therapies. Zoledronate therapy for 10 days sup-
pressed bone resorption with retention of dead bone
and appeared to have a negative effect on soft-tissue
healing. PTH therapy for 10 days promoted soft-
tissue repair and integrity and hard-tissue healing.
These findings emphasize the importance of mini-
mizing trauma and, hence, dead bone accumulation
when invasive periodontal procedures, such as im-
plant placement, osseous surgeries, and tooth ex-
tractions, are performed in osteoporosis patients
taking bisphosphonates.
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